Bio + Health

COVID-19 is Testing the World

a16z editorial Posted April 3, 2020

COVID-19 is Testing the World Table of Contents

This post first appeared as an issue of the a16z Bio Newsletter. Subscribe to stay on top of the latest trends in bio and healthcare.

IN THIS ISSUE: 

  • How we are staying up to date with COVID-19: Reliable resources in these unpredictable times
  • Virtual medicine’s mainstream moment: Adoption and development get a big push
  • Coronavirus tests—what we have and what we need: What diagnostic tests measure and how
  • Speed of innovation vs safety: Balancing and integrating RCT and RWE
  • The fight over electronic health data—the sequel: New HHS rules free up patient data

 

How we are staying up to date with COVID-10

Right now, accurate and reliable information is absolutely essential. We are maintaining a list of select Coronavirus Resources & Readings, which we use to keep up to date with the latest information, the response, and the global impact. We hope you’ll find it useful too.

Virtual medicine's mainstream moment

As the COVID-19 epidemic continues to spread, so does the strain on the healthcare system. Virtual medicine, aka “telemedicine,” has been slowly gaining traction in recent years with both providers and consumers. But thanks to the novel coronavirus, the demand has skyrocketed overnight. With most of us sheltering in place and aiming to minimize contact between potentially infected individuals, virtual care is now the first stop for many seeking healthcare. 

In this podcast, a16z general partners Julie Yoo and Vijay Pande discuss with Hanne Tidnam how virtual medicine gives us an opportunity to rethink and re-engineer how care is delivered. What it is good at, what are the current limitations, what’s changing, what needs to change… and where could it eventually go one day? 

LISTEN HERE

Coronavirus test—what we have and what we need

We’ve been hearing about lab tests nonstop the past few weeks—tests from the CDC, tests from various companies, tests from abroad—as it’s important in diagnosing, eventually easing social distancing guidelines, and transitioning our economy back to business as usual. COVID-19 has cast a light on just how fractured and varied the diagnostics landscape is, with many different methods, facilities, and access points for testing, each of which has advantages and disadvantages. In this blog post, deal partner Judy Savitskaya and general partner Jorge Conde break down what’s actually happening inside these tests—such as the differences between tests that look for active infections, and those which can tell us whether a patient has ever been infected and is now immune—and provide a glimpse into innovative technologies in development for the future. 

RELATED: Also check out this podcast with Dave King, executive chairman of one of the largest clinical lab networks in the world (with Jorge Conde and Hanne Tidnam), to learn more about how new tests, and technologies, are integrated—as well as where the modern lab itself is going (will it be unbundled?).

LISTEN HERE

Speed of innovation vs safety

If the best way to know whether a medicine is safe and effective is through a randomized controlled trial (RCT) and clinical trials, then where does (and doesn’t) real-world data and real-world evidence (RWE) come in? The topic is especially heated lately given recent concerns and claims around particular drugs in the context of the novel coronavirus pandemic. So in this 16-ish minutes episode and tweetstorm, general partner Vijay Pande breaks down the debate between RWE vs. RCT in conversation with Sonal Chokshi. Is it a tradeoff between speed and safety, or is that a false dichotomy altogether? How has, and could, the role of the FDA and payors evolve here? 

LISTEN HERE

The fight over electronic health data—the sequel

In last month’s newsletter, we discussed EPIC’s “letter heard around the healthcare world” opposing the proposed draft rules from the Department of Health and Human Services regarding liquidity, interoperability, and portability in healthcare data. This month, these rules became official. In this episode of our news show 16 Minutes, a16z’s General Partner Julie Yoo and Venkat Mocherla discuss with Sonal Chokshi the content of the rules; what they mean for hospitals—particularly in this critical time in healthcare; the implications for providers and payers; security concerns; and opportunities for startups and incumbents in this space.

LISTEN HERE

Want More a16z Bio + Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Learn More
Recommended For You
General

Big Ideas 2026: Part 3

a16z New Media
General

Big Ideas 2026: Part 2

a16z New Media
General

Big Ideas 2026: Part 1

a16z New Media
Bio + Health

The COVID-19 crisis continues: How we got here and how we move on

a16z editorial and Jorge Conde

Want More Bio+Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Sign Up On Substack

Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.

The contents in here — and available on any associated distribution platforms and any public a16z online social media accounts, platforms, and sites (collectively, “content distribution outlets”) — should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on a16z content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, posts may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. All content speaks only as of the date indicated.

Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.

There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.

With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.

For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.